Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We investigated improvements in overactive bladder symptoms and depressive symptoms after solifenacin treatment in overactive bladder patients with or without depressive symptoms. Methods: We performed a prospective study of patients who had been diagnosed with overactive bladder from July 2013 to June 2014. Based on the Beck Depression Inventory questionnaire, the test subjects were divided into group 1, without depressive symptoms (0–9 points), and group 2, with depressive symptoms (10 or more points). The patients were administered 5 mg of solifenacin for 3 months. The following outcomes were analyzed at the first visit, 4 weeks, and 12 weeks: the overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS), patients’ perceptions of their bladder condition, and the Beck Depression Inventory. Results: A total of 72 patients participated, and 52 patients completed the study. Most outcome measures showed improvements in both groups at weeks 4 and 12. Especially in group 2, the questionnaires showed significant improvements from baseline to week 12, indicating that solifenacin was effective at treating overactive bladder symptoms (group 1 vs. group 2: OABSS, −2.67±0.80 vs. −3.00±0.77; P<0.01; IPSS-total, −2.14±2.15 vs. −4.94±1.70; P<0.01). Statistically significant decreases in the Beck Depression Inventory score from baseline to weeks 4 and 12 were observed in group 2 (group 1 vs. group 2: 1.43±0.74 vs. −2.68±4.05 at week 4, P<0.001; 0.10±3.37 vs. −5.52±5.82 at week 12, P<0.001). Conclusions: In overactive bladder patients with depressive symptoms, solifenacin can help improve quality of life and depressive symptoms at the same time.
Abstract
Purpose: We investigated improvements in overactive bladder symptoms and depressive symptoms after solifenacin treatment in overactive bladder patients with or without depressive symptoms. Methods: We performed a prospective study of patients who had been diagnosed with overactive bladder from July 2013 to June 2014. Based on the Beck Depression Inventory questionnaire, the test subjects were divided into group 1, without depressive symptoms (0–9 points), and group 2, with depressive symptoms (10 or more points). The patients were administered 5 mg of solifenacin for 3 months. The following outcomes were analyzed at the first visit, 4 weeks, and 12 weeks: the overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS), patients’ perceptions of their bladder condition, and the Beck Depression Inventory. Results: A total of 72 patients participated, and 52 patients completed the study. Most outcome measures showed improvements in both groups at weeks 4 and 12. Especially in group 2, the questionnaires showed significant improvements from baseline to week 12, indicating that solifenacin was effective at treating overactive bladder symptoms (group 1 vs. group 2: OABSS, −2.67±0.80 vs. −3.00±0.77; P<0.01; IPSS-total, −2.14±2.15 vs. −4.94±1.70; P<0.01). Statistically significant decreases in the Beck Depression Inventory score from baseline to weeks 4 and 12 were observed in group 2 (group 1 vs. group 2: 1.43±0.74 vs. −2.68±4.05 at week 4, P<0.001; 0.10±3.37 vs. −5.52±5.82 at week 12, P<0.001). Conclusions: In overactive bladder patients with depressive symptoms, solifenacin can help improve quality of life and depressive symptoms at the same time.
참고문헌 (28)
- Wein AJ, "Diagnosis and treatment of the overactive bladder", Urology, 62(5 Suppl 2), pp.20~27 (2003)
- Coyne KS, "National community prevalence of overactive bladder in the United States stratified by sex and age", Urology, 77, pp.1081~1087 (2011)
- Ganz ML, "Economic costs of overactive bladder in the United States", Urology, 75, pp.526~532 (2010)
- Liberman JN, "Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey", Urology, 57, pp.1044~1050 (2001)
- Coyne KS, "The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study", BJU Int, 101, pp.1388~1395 (2008)
- Lee KS, "Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data’", BJU Int, 105, pp.1565~1570 (2010)
- D’Souza AO, "Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan", J Manag Care Pharm, 14, pp.291~301 (2008)
- Kessler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 62, pp.593~602 (2005)
- Dmochowski RR, "Extended-release trospium chloride improves quality of life in overactive bladder", Value Health, 13, pp.251~257 (2010)
- Choi HR, "Translation Validity and Reliability of I-PSS Korean Version", Korean J Urol, 37, pp.659~665 (1996)
- Rogers RG, "Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence", Curr Med Res Opin, 25, pp.2159~2165 (2009)
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Kendall PC, "Issues and recommendations regarding use of the Beck Depression Inventory", Cogn Ther Res, 11, pp.289~299 (1987)
- Eduardo de Paula Miranda, "Nocturia is the Lower Urinary Tract Symptom With Greatest Impact on Quality of Life of Men From a Community Setting", International Neurourology Journal, 18(2), pp.86~90 (2014), 대한배뇨장애요실금학회
- Melville JL, "Major depression and urinary incontinence in women: temporal associations in an epidemiologic sample", Am J Obstet Gynecol, 201, pp.490.e1~490.e7 (2009)
- Angell J, "Association of depression and urolithiasis", Urology, 79, pp.518~525 (2012)
- Chiaffarino F, "Impact of urinary incontinence and overactive bladder on quality of life", Eur Urol, 43, pp.535~538 (2003)
- Irwin DE, "Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries", BJU Int, 97, pp.96~100 (2006)
- Moussavi S, "Depression, chronic diseases, and decrements in health: results from the World Health Surveys", Lancet, 370, pp.851~858 (2007)
- Brown P, "The global burden of disease: summary" (1996), Harvard School of Public Health
- Nicolson P, "It’s just the worry about not being able to control it! A qualitative study of living with overactive bladder", Br J Health Psychol, 13(Pt 2), pp.343~359 (2008)
- Anger JT, "Women’s experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups", Neurourol Urodyn, 30, pp.1295~1299 (2011)
- Milsom I, "Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS", Urology, 80, pp.90~96 (2012)
- 유은상, "The Impact of Overactive Bladder on Health-Related Quality of Life, Sexual Life and Psychological Health in Korea", International Neurourology Journal, 15(3), pp.143~151 (2011), 대한배뇨장애요실금학회
- Andersson KE, "Antimuscarinics for treatment of overactive bladder", Lancet Neurol, 3, pp.46~53 (2004)
- Khullar V, "The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis", Urology, 68(2 Suppl), pp.38~48 (2006)
- Choo MS, "Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study", Int J Clin Pract, 62, pp.1675~1683 (2008)
- Kim KS, "Tamsulosin treatment affecting patient-reported outcomes in benign prostatic hyperplasia-associated depressive symptoms", Urology, 87, pp.172~177 (2016)